Table 1.
Baseline comorbidities and patient population characteristics.
| Reference, year | MRI protocol | Subgroup | Number of patients | Time to MRI (d)a,b | Age (y) | Male sex | BMI (kg/m2) | Diabetesc | Hyper-cholesterolemiac | Hypertensionc | Smokingc |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amabile et al,10 2012 | T2-weighted | No IMH | 103 | 5.5 ± 3.4a | 57.5 | 85 (82.5%) | 26.6 | 16 (15.5%) | 35 (34.0%) | 38 (36.9%) | 63 (61.2%) |
| IMH | 11 | 4.7 ± 1.9a | 58.3 | 10 (90.9%) | 26.5 | 3 (27.3%) | 4 (36.4%) | 5 (45.5%) | 5 (45.5%) | ||
| Amier et al,12 2017 | T2-weighted | No IMH | 188 | 5.5 ± 1.8a | 59.5 | 148 (78.7%) | 27 | 29 (15.4%) | 61 (32.4%) | 85 (45.2%) | 144 (76.6%) |
| IMH | 222 | 57.7 | 195 (87.8%) | 27.2 | 31 (14.0%) | 82 (36.9%) | 78 (35.1%) | 174 (78.4%) | |||
| Beek et al,13 2010 | T2-STIR | No IMH | 23 | 4.3 ± 2.1a | 59 | 21 (91.3%) | - | 2 (8.7%) | 5 (21.7%) | 6 (26.1%) | 14 (60.9%) |
| IMH | 22 | 5.7 ± 2.0a | 54 | 19 (86.4%) | - | 0 (0%) | 8 (36.4%) | 6 (27.3%) | 14 (63.6%) | ||
| Bekkers et al,14 2010 | T2-STIR | No IMH | 51 | 5 ± 2 a | 60.6 | 33 (64.7%) | - | 5 (9.8%) | 14 (27.5%) | 23 (45.1%) | 42 (82.4%) |
| IMH | 39 | 59 | 32 (82.1%) | - | 1 (2.6%) | 11 (28.2%) | 12 (30.8%) | 36 (92.3%) | |||
| Carrick et al,15 2016 | T2∗-weighted | No IMH | 144 | 2.1 ± 1.8a | 58.6 | 103 (71.5%) | 27.8 | 13 (9.0%) | 37 (25.7%) | 40 (27.8%) | 83 (57.6%) |
| IMH | 101 | 59 | 84 (83.2%) | 28 | 15 (14.9%) | 31 (30.7%) | 37 (36.6%) | 70 (69.3%) | |||
| Ding et al,16 2015 | T2-STIR | No IMH | 55 | 5b | 59.2 | 47 (85.5%) | - | 25 (45.5%) | 28 (50.9%) | 32 (58.2%) | 40 (72.7%) |
| IMH | 53 | 57.6 | 43 (81.1%) | - | 14 (26.4%) | 31 (58.5%) | 26 (49.1%) | 41 (77.4%) | |||
| Eitel et al,17 2011 | T2-STIR | No IMH | 224 | 3b | 65 | 162 (72.3%) | - | 49 (21.9%) | 81 (36.2%) | 146 (65.2%) | 84 (37.5%) |
| IMH | 122 | 62 | 94 (77.0%) | - | 29 (23.8%) | 40 (32.8%) | 76 (62.3%) | 56 (45.9%) | |||
| Ganame et al,11 2009 | T2-STIR | No IMH | 74 | 2b | 60 | 60 (81.1%) | - | 7 (9.5%) | 38 (51.4%) | 19 (25.7%) | 33 (44.6%) |
| IMH | 24 | 57.7 | 24 (100.0%) | - | 3 (12.5%) | 16 (66.7%) | 8 (33.3%) | 16 (66.7%) | |||
| Husser et al,18 2013 | T2-STIR | No IMH | 202 | 6b | 59 | 163 (80.7%) | - | 28 (13.9%) | 79 (39.1%) | 92 (45.5%) | 114 (56.4%) |
| IMH | 102 | 57 | 81 (79.4%) | - | 25 (24.5%) | 37 (36.3%) | 49 (48.0%) | 68 (66.7%) | |||
| Kandler et al,19 2014 | T2∗-weighted | No IMH | 75 | 2.9b | 62 | 53 (70.7%) | 28.7 | 14 (18.7%) | 32 (42.7%) | 51 (68.0%) | 37 (49.3%) |
| IMH | 76 | 60 | 61 (80.3%) | 27.9 | 18 (23.7%) | 20 (26.3%) | 52 (68.4%) | 44 (57.9%) | |||
| Ma et al,20 2018 | T2∗-weighted | No IMH | 35 | 3.0 ± 1.1a | 56 | - | 24.8 | 7 (20.0%) | 4 (11.4%) | 19 (54.3%) | 27 (77.1%) |
| IMH | 28 | 51.5 | - | 25.5 | 3 (10.7%) | 9 (32.1%) | 10 (35.7%) | 23 (82.1%) | |||
| Mather et al,21 2011 | T2- and T2∗-weighted | No IMH | 36 | 2b | 57.5 | 32 (88.9%) | - | 1 (2.8%) | 19 (52.8%) | 12 (33.3%) | 19 (52.8%) |
| IMH | 12 | 56 | 11 (91.7%) | - | 3 (25.0%) | 8 (66.7%) | 4 (33.3%) | 6 (50.0%) | |||
| O’Regan et al,27 2010 | T2∗-weighted | No IMH | 21 | 3.1 ± 2.0a | 54 | 20 (95.2%) | - | 1 (4.8%) | - | 6 (28.6%) | 15 (71.4%) |
| IMH | 29 | 55 | 28 (96.6%) | - | 6 (20.7%) | - | 8 (27.6%) | 14 (48.3%) | |||
| Ochiai et al,28 1999 | T2∗-weighted | No IMH | 26 | 5.7b | 63 | 17 (65.4%) | - | - | - | - | - |
| IMH | 13 | 63 | 7 (53.8%) | - | - | - | - | - | |||
| Reinstadler et al,22 2019 | T2∗-weighted | No IMH | 204 | 3b | 61 | 131 (64.2%) | 28 | 32 (15.7%) | 78 (38.4%) | 130 (63.7%) | 98 (49.2%) |
| IMH | 60 | 59 | 44 (73.3%) | 26 | 7 (11.7%) | 17 (28.3%) | 37 (61.7%) | 26 (45.6%) | |||
| Spinelli et al,24 2018 | T2-STIR/speckle-tracking echocardiography analysis | No IMH | 45 | - | 58.6 | 39 (86.7%) | - | 13 (28.9%) | 22 (48.9%) | 22 (48.9%) | 26 (57.8%) |
| IMH | 42 | 59.3 | 38 (90.5%) | - | 14 (33.3%) | 19 (45.2%) | 20 (47.6%) | 23 (54.8%) | |||
| Symons et al,25 2015 | T2-STIR | No IMH | 152 | 2.9b | 59 | 123 (80.9%) | - | - | - | 46 (30.3%) | - |
| IMH | 34 | 59 | 32 (94.1%) | - | - | - | 14 (41.2%) | - | |||
| Zhao et al,26 2016 | T2-STIR | No IMH | 35 | 8b | 57.7 | 33 (94.3%) | - | 14 (40.0%) | 13 (37.1%) | 19 (54.3%) | 14 (40.0%) |
| IMH | 46 | 57 | 43 (93.5%) | - | 18 (39.1%) | 30 (65.2%) | 26 (56.5%) | 18 (39.1%) |
BMI, body mass index; IMH, intramyocardial hemorrhage; MRI, magnetic resonance imaging; T2-STIR, T2-weighted imaging with short-tau inversion recovery magnetization preparation.
a
Values are reported as mean ± SD number of days.
b
Values are reported as median number of days.
c
Values expressed as n (%).